BioNTech SE

Alpha Score of 38 reflects weak overall profile with moderate momentum, moderate value, poor quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

BioNTech SE is a German multinational biotechnology company headquartered in Mainz, specializing in the development of immunotherapies and vaccines for cancer and infectious diseases. Founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber, it leverages advanced platforms like mRNA technology, next-generation immunomodulators, targeted therapies, and antibody-drug conjugates to address unmet medical needs. The company gained global prominence through its partnership with Pfizer to develop Comirnaty, the first approved mRNA-based COVID-19 vaccine, while advancing a diversified oncology pipeline with late-stage programs targeting various cancer stages, from early high-risk to metastatic diseases. BioNTech SE operates a global network of research, manufacturing, and commercial sites across Europe, North America, Asia, Australia, and Africa, including innovative BioNTainer systems for scalable mRNA production. Recent strategic moves, such as acquiring InstaDeep for AI-driven drug discovery, CureVac for enhanced mRNA capabilities, and Biotheus for advanced drug candidates, underscore its commitment to innovation. Employing over 6,000 professionals, BioNTech SE plays a pivotal role in transforming oncology and infectious disease treatments through synergistic multi-modal approaches and computational advancements.